Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of bre...

Full description

Bibliographic Details
Authors: Colomer, Ramon, Aranda-Lopez, Ignacio, Albanell Mestres, Joan, García-Caballero, Tomás, Ciruelos, Eva, Lopez-García, M. A., Cortés, Javier, Rojo, Federico, Martín, M., Palacios-Calvo, J.
Format: article
Status:Published version
Publication Date:2018
Country:España
Institution:Universitat Pompeu Fabra
Repository:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/35642
Online Access:http://hdl.handle.net/10230/35642
http://dx.doi.org/10.1007/s12094-017-1800-5
Access Level:Open access
Keyword:Marcadors bioquímics
Mama -- Càncer
Breast neoplasm
Diagnostic
Gene expression profiling
Prognostic
Therapy predictive
id ES_4ef86358ccd4ddd39b1ab620ab6cfbb9
oai_identifier_str oai:repositori.upf.edu:10230/35642
network_acronym_str ES
network_name_str España
repository_id_str
spelling Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of PathologyColomer, RamonAranda-Lopez, IgnacioAlbanell Mestres, JoanGarcía-Caballero, TomásCiruelos, EvaLopez-García, M. A.Cortés, JavierRojo, FedericoMartín, M.Palacios-Calvo, J.Marcadors bioquímicsMama -- CàncerBreast neoplasmDiagnosticGene expression profilingPrognosticTherapy predictiveThis consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of breast cancer the histologic grade and the alpha-estrogen receptor (ER), progesterone receptor, Ki-67 and HER2 status, in order to assist prognosis and establish therapeutic options, including hormone therapy, chemotherapy and anti-HER2 therapy. One of the four available genetic prognostic platforms (MammaPrint®, Oncotype DX®, Prosigna® or EndoPredict®) may be used in node-negative ER-positive patients to establish a prognostic category and decide with the patient whether adjuvant treatment may be limited to hormonal therapy. Newer technologies including next-generation sequencing, liquid biopsy, tumour-infiltrating lymphocytes or PD-1 determination are at this point investigational.SpringerOpen201820182018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/35642http://dx.doi.org/10.1007/s12094-017-1800-5reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésClinical and Translational Oncology. 2018 Jul;20(7):815-26Copyright © The Author(s) 2017. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/356422026-06-12T07:21:37Z
dc.title.none.fl_str_mv Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
title Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
spellingShingle Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Colomer, Ramon
Marcadors bioquímics
Mama -- Càncer
Breast neoplasm
Diagnostic
Gene expression profiling
Prognostic
Therapy predictive
title_short Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
title_full Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
title_fullStr Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
title_full_unstemmed Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
title_sort Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
dc.creator.none.fl_str_mv Colomer, Ramon
Aranda-Lopez, Ignacio
Albanell Mestres, Joan
García-Caballero, Tomás
Ciruelos, Eva
Lopez-García, M. A.
Cortés, Javier
Rojo, Federico
Martín, M.
Palacios-Calvo, J.
author Colomer, Ramon
author_facet Colomer, Ramon
Aranda-Lopez, Ignacio
Albanell Mestres, Joan
García-Caballero, Tomás
Ciruelos, Eva
Lopez-García, M. A.
Cortés, Javier
Rojo, Federico
Martín, M.
Palacios-Calvo, J.
author_role author
author2 Aranda-Lopez, Ignacio
Albanell Mestres, Joan
García-Caballero, Tomás
Ciruelos, Eva
Lopez-García, M. A.
Cortés, Javier
Rojo, Federico
Martín, M.
Palacios-Calvo, J.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Marcadors bioquímics
Mama -- Càncer
Breast neoplasm
Diagnostic
Gene expression profiling
Prognostic
Therapy predictive
topic Marcadors bioquímics
Mama -- Càncer
Breast neoplasm
Diagnostic
Gene expression profiling
Prognostic
Therapy predictive
description This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of breast cancer the histologic grade and the alpha-estrogen receptor (ER), progesterone receptor, Ki-67 and HER2 status, in order to assist prognosis and establish therapeutic options, including hormone therapy, chemotherapy and anti-HER2 therapy. One of the four available genetic prognostic platforms (MammaPrint®, Oncotype DX®, Prosigna® or EndoPredict®) may be used in node-negative ER-positive patients to establish a prognostic category and decide with the patient whether adjuvant treatment may be limited to hormonal therapy. Newer technologies including next-generation sequencing, liquid biopsy, tumour-infiltrating lymphocytes or PD-1 determination are at this point investigational.
publishDate 2018
dc.date.none.fl_str_mv 2018
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/35642
http://dx.doi.org/10.1007/s12094-017-1800-5
url http://hdl.handle.net/10230/35642
http://dx.doi.org/10.1007/s12094-017-1800-5
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clinical and Translational Oncology. 2018 Jul;20(7):815-26
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv SpringerOpen
publisher.none.fl_str_mv SpringerOpen
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407790389264384
score 15,81155

Similar Items